Shobha Asthana, MD
Neurology with Special Qualifications in Child Neurology · Belle Vernon, PANPI 1760464408
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.8% of the total across 335 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,446 and has fallen 78.4% since, to $529 in 2025.
Across 335 payments — averaging $17.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$1K
- Biogen$502
- Neurocrine Biosciences, Inc.$384
- Acorda Therapeutics, Inc$348
- Sanofi$334
- Novartis$294
- plus $3K from 31 others
What the payments were for
- Speaking & faculty fees$2895%
- Food & beverage$5,69995%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 54 | $1,046 |
| Biogen | 29 | $502 |
| Neurocrine Biosciences, Inc. | 17 | $384 |
| Acorda Therapeutics, Inc | 20 | $348 |
| Sanofi | 21 | $334 |
| Novartis | 21 | $294 |
| Greenwich Biosciences, Inc. | 13 | $280 |
| SK Life Science, Inc. | 10 | $230 |
| Lilly USA, LLC | 13 | $214 |
| Tanabe Pharma America, Inc. | 11 | $211 |
| AbbVie(2 entities) | 12 | $187 |
| Vertical Pharmaceuticals, LLC | 11 | $158 |
| Argenx US, Inc. | 8 | $147 |
| Sunovion Pharmaceuticals Inc. | 8 | $141 |
| Livanova USA, Inc. | 9 | $137 |
| Neurelis, Inc. | 8 | $136 |
| Amgen | 9 | $133 |
| AstraZeneca | 6 | $128 |
| Jazz Pharmaceuticals Inc. | 6 | $122 |
| Vanda Pharmaceuticals Inc. | 5 | $122 |
| EMD Serono, Inc. | 5 | $98 |
| Bristol Myers Squibb | 6 | $94 |
| Lundbeck LLC | 5 | $83 |
| Aquestive Therapeutics, Inc. | 5 | $77 |
| Johnson & Johnson | 3 | $66 |
| Supernus Pharmaceuticals, Inc. | 3 | $45 |
| GE HealthCare | 3 | $44 |
| Genentech USA, Inc. | 2 | $42 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| Amneal Pharmaceuticals LLC | 2 | $33 |
| Teva Pharmaceuticals USA, Inc. | 1 | $29 |
| Harmony Biosciences LLC | 2 | $26 |
| Banner Life Sciences, LLC | 1 | $24 |
| Mirum Pharmaceuticals, Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Acadia Pharmaceuticals Inc | 1 | $14 |
| Mallinckrodt Enterprises LLC | 1 | $13 |
How this compares
$6,013 in reported general payments places this provider in the 75th percentile of 83 neurology with special qualifications in child neurology providers in Pennsylvania.
See all neurology with special qualifications in child neurology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rebif RebidoseInterferon Beta-1a/Albumin | 13 | $133,096 |
| BetaseronInterferon Beta-1b | 14 | $127,800 |
| Teriflunomide | 11 | $27,521 |
| LinzessLinaclotide | 17 | $8,922 |
| NayzilamMidazolam | 13 | $8,511 |
| Gabapentin | 243 | $6,657 |
| Levetiracetam | 265 | $5,146 |
| Lacosamide | 38 | $4,946 |
| Carbamazepine ErCarbamazepine | 23 | $2,976 |
| Pregabalin | 89 | $2,242 |
| Bromocriptine Mesylate | 12 | $1,913 |
| Lamotrigine | 81 | $1,648 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 108 | $1,450 |
| Amitriptyline Hcl | 85 | $1,442 |
| Baclofen | 109 | $1,401 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $187 | $8,92217 claims |
| UCB, Inc.Nayzilam | $1,046 | $8,51113 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Pyridostigmine Bromide | $33 | $92063 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 83 neurology with special qualifications in child neurology providers in Pennsylvania.
Other neurology with special qualifications in child neurology in Belle Vernon
- Anne MorseDanville$582K
- John BrandsemaPhiladelphia$526K
- Susan MatesanzPhiladelphia$138K
- Elizabeth KichulaPhiladelphia$90K
- Dennis DlugosPhiladelphia$88K
- Alexandra KornbluhPhiladelphia$88K
- Nicholas AbendPhiladelphia$56K
- Sabrina YumPhiladelphia$33K
- Eric MarshPhiladelphia$28K
- Christina SzperkaPhiladelphia$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.